Superbug Antibiotic Defence Uncovered
Researcher Albert Berghuis has found out one of the ways in which the Staphylococcus aureus bacterium, a multi-drug resistant 'superbug,' is able to fight off one of the latest drugs of last resort used to treat it.
Dr. Berghuis' research team in McGill's Departments of Biochemistry and Microbiology & Immunology observed a mechanism by which Staphylococcus aureus (SA) can resist the antibiotic Synercid, by attacking one of the drug's ingredients with an enzyme, Virginiamycin B lyase (Vgb). The findings appear in the early online edition of the journal Proceedings of the National Academy of Sciences (PNAS).
"Specifically, we determined the three-dimensional structure of the enzyme and visualized how it interacts with Synercid," said Dr. Berghuis, Canada Research Chair in Structural Biology. "This reveals for the first time how Staph aureus can detoxify quinupristin, one of the component drugs of Synercid. More important, though, is that it also suggests how we can optimize Synercid in such a way that it will remain active in resistant bacteria that possess Vgb."
The researchers chose to use Synercid in their study because the drug, which received accelerated approval from the Food and Drug Administration in 1999, was specifically designed to treat infections caused by superbugs.
Dr. Berghuis, whose lab conducted the study in collaboration with colleagues at McMaster University, said the team will now focus on developing a compound to replace quinupristin in Synercid. They will also continue examining other drugs to see if a similar modification can help counteract drug resistance